Status:
COMPLETED
Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)
Lead Sponsor:
Groupe Hospitalier Pitie-Salpetriere
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Hematological Abnormality
Hematotoxicity
Eligibility:
All Genders
18+ years
Brief Summary
Several drugs and chemotherapies seem to have an impact on the hematological system. This study investigates reports of hematological toxicities, including the International classification of disease ...
Detailed Description
Several drugs and chemotherapies seem to have an impact on the hematological system and are responsible of a wide range of hematological side effects. Those are poorly described, due to the modificati...
Eligibility Criteria
Inclusion
- Case reported in the WHO's pharmacovigilance database till 01/02/2019
Exclusion
- Chronology not compatible between the drug and the toxicity
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 8 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03828942
Start Date
February 1 2019
End Date
April 8 2023
Last Update
April 13 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM
Paris, France, 75013
2
Rhumatology department, CHU Strasbourg, Hautepierre hospital
Strasbourg, France, 67098